United Therapeutics Strikes $525 Million Deal to Eliminate Ralinepag Royalties
Bitget2026/11/04 12:03- United Therapeutics entered a $525 million upfront agreement with Pfizer subsidiary Arena Pharmaceuticals to eliminate all ralinepag royalty obligations.
- The amendment removes a low double-digit royalty on net sales of all ralinepag formulations.
- A $250 million milestone remains payable upon the first US marketing approval of inhaled ralinepag for pulmonary arterial hypertension.
- A $150 million milestone remains payable upon first oral ralinepag marketing approval for any indication in Japan or specified European markets.
- Oral ralinepag’s application for pulmonary arterial hypertension remains under FDA review, with a June 24, 2027, user fee action date.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
SoftBank develops contingency plans for slowdown in US data center business, considers shifting to other countries
A new twist has emerged in the US AI data center investment boom. SoftBank is preparing for cooling US demand and a deteriorating political environment, and does not rule out shifting data center construction priorities to other countries. As cross-border computing power delivery capability improves and investment returns come under question, the logic behind AI infrastructure expansion is loosening, and over $3.5 trillion in infrastructure investment now faces potential impairment risks.
Quantumrail Cancels 10 Billion Won Convertible Bond Offering
Crypto prices
More
